Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inhibikase Therapeutics, Inc.IKT · Entity 5838 | Director | February 14, 2025 | February 20, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inhibikase Therapeutics, Inc.
Report date February 14, 2025 · Filed February 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.35 · Expires 2035-02-14 | Direct | 22,640 |
Reported balance
After 2025-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-14 · Grant · Acquired 22,640 · Balance 22,640 F1: The options vested and became exercisable on February 14, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vested and became exercisable on February 14, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2025 Filed Feb 20, 2025 01:16 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (Right to Buy) · Derivative | 22,640 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0000950170-25-023592 · ownership.xml · derivative · entry 1 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,640 Underlying: Common Stock · 22,640 shares Expires 2035-02-14 F1 · derivative.exercise_date: The options vested and became exercisable on February 14, 2025. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 12 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-07-16 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 11 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2031-07-16 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (Right to Buy) · Derivative | 6,667 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 10 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2030-06-30 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,667 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 9 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,667 shares Expires 2030-06-30 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (Right to Buy) · Derivative | 6,667 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 8 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2029-06-24 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,667 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 7 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,667 shares Expires 2029-06-24 F1 · derivative.exercise_price: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (Right to Buy) · Derivative | 3,780 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 6 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,780 Underlying: Common Stock · 3,780 shares Expires 2028-06-25 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,780 | $0.00 Strike: $17.52 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 5 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,780 shares Expires 2028-06-25 F1 · derivative.exercise_price: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (Right to Buy) · Derivative | 1,138 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 4 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,138 Underlying: Common Stock · 1,138 shares Expires 2027-12-22 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,138 | $0.00 Strike: $60.00 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 3 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,138 shares Expires 2027-12-22 F1 · derivative.exercise_price: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F4 · derivative.expiration_date: The acquisition of the reported option was reported in a Form 4 filed on December 29, 2020, which mistakenly reported the expiration date as December 22, 2030. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (Right to Buy) · Derivative | 21,854 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 2 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,854 Underlying: Common Stock · 21,854 shares Expires 2026-07-28 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | Disposition to issuerStock Option (Right to Buy) · Derivative | 21,854 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 1 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,854 shares Expires 2026-07-28 F1 · derivative.exercise_price: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 23:39 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (Right to Buy) · Derivative | 316,647 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0000950170-25-003125 · ownership.xml · derivative · entry 3 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,647 Underlying: Common Stock · 316,647 shares Expires 2035-01-03 F3 · derivative.exercise_date: The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series B-1 Warrants in an amount proportional to the actual number of Series B-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 23:39 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (Right to Buy) · Derivative | 172,191 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0000950170-25-003125 · ownership.xml · derivative · entry 2 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,191 Underlying: Common Stock · 172,191 shares Expires 2035-01-03 F2 · derivative.exercise_date: The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series A-1 Warrants in an amount proportional to the actual number of Series A-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 23:39 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (Right to Buy) · Derivative | 344,452 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-003125 · ownership.xml · derivative · entry 1 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 344,452 Underlying: Common Stock · 344,452 shares Expires 2035-01-03 F1 · derivative.exercise_date: The options vested and became exercisable on October 9, 2024. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 21:18 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0000950170-24-084655 · ownership.xml · derivative · entry 1 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-07-16 F1 · derivative.exercise_date: The options will vest on the earlier of July 16, 2025 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date. Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 01:11 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (right to buy) · Derivative | 6,667 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0000950170-23-031850 · ownership.xml · derivative · entry 1 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2030-06-30 F1 · derivative.exercise_date: The options will vest on the earlier of June 30, 2024 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date. Read SEC document |
| June 24, 2022 Filed Jun 29, 2022 01:00 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0001209191-22-039712 · doc4.xml · derivative · entry 1 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-06-24 F1 · derivative.exercise_date: This entire stock option grant will vest 100% in a single tranche on the earlier of June 24, 2023 or the day prior to the next annual meeting of stockholders. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 23:10 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (right to buy) · Derivative | 22,677 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001104659-21-086988 · tm2120992d2_4.xml · derivative · entry 1 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,677 Underlying: Common Stock · 22,677 shares Expires 2028-06-25 Read SEC document |
| December 22, 2020 Filed Dec 30, 2020 02:52 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (right to buy) · Derivative | 6,825 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001104659-20-140309 · tm2039455d3_form4.xml · derivative · entry 1 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,825 Underlying: Common Stock · 6,825 shares Expires 2030-12-22 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.